Trial · NCT03120949
Adverse events430
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
201 to 220 of 430
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Cardiac failure congestive | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 0 | 1,043 | 0 |
| serious | Cardiac failure congestive | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 1 | 1,061 | 1 |
| serious | Coronary artery occlusion | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 1 | 1,043 | 1 |
| serious | Coronary artery occlusion | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 0 | 1,061 | 0 |
| serious | Coronary artery stenosis | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 0 | 1,043 | 0 |
| serious | Coronary artery stenosis | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 1 | 1,061 | 1 |
| serious | Myocardial infarction | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 0 | 1,043 | 0 |
| serious | Myocardial infarction | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 1 | 1,061 | 1 |
| serious | Right ventricular dysfunction | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 0 | 1,043 | 0 |
| serious | Right ventricular dysfunction | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 1 | 1,061 | 1 |
| serious | Sinus tachycardia | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 0 | 1,043 | 0 |
| serious | Sinus tachycardia | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 1 | 1,061 | 1 |
| serious | Stress cardiomyopathy | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 1 | 1,043 | 1 |
| serious | Stress cardiomyopathy | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 0 | 1,061 | 0 |
| serious | Supraventricular tachyarrhythmia | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 0 | 1,043 | 0 |
| serious | Supraventricular tachyarrhythmia | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 1 | 1,061 | 1 |
| serious | Ventricular fibrillation | Cardiac disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 1 | 1,043 | 1 |
| serious | Ventricular fibrillation | Cardiac disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 0 | 1,061 | 0 |
| serious | Diverticular perforation | Gastrointestinal disorders | Treatment Arm 1: OKZ 64 mg q4w + MTX | 1 | 1,043 | 1 |
| serious | Diverticular perforation | Gastrointestinal disorders | Treatment Arm 2: OKZ 64 mg q2w + MTX | 2 | 1,061 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03120949/events?page=11